Clinical Trials Browser

NIH × incomplete Freund's adjuvant × Clear all

NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

Phase 2 Terminated

Neoplasms, Ovarian Neoplasms

NCT00062036 2017-07-02

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase 2 Terminated

50 enrolled 13 charts

Melanoma

NCT00091338 2015-04-30

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT00089063 2015-04-15

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Phase 2 Completed

Uveal Melanoma, Melanoma

NCT00001703 2014-07-25

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Phase 2 Terminated

6 enrolled 8 charts

Carcinoma, Renal Cell

NCT00104780 2013-11-06

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00003568 2013-06-26

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019383 2013-06-20

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019487 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019721 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00032045 2013-06-20

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Phase 2 Completed

Uveal Melanoma, Melanoma

NCT00019994 2013-06-19

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00020358 2013-06-19

Vaccine Therapy in Treating Patients With Melanoma

Phase 2 Completed

Melanoma

NCT00021164 2013-06-19

Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 2 Completed

Melanoma

NCT00022438 2013-06-19

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Phase 2 Completed

Melanoma

NCT00072085 2013-06-19

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00079144 2013-06-19

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00303836 2013-06-06

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase 2 Terminated

Melanoma

NCT00091143 2013-04-04

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT00006243 2013-01-25

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Phase NA Completed

Melanoma

NCT00109811 2013-01-23

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00091104 2012-03-15

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT00006385 2011-11-08

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma